Background: Gemcitabine (Gemzar®) and 5-fluorouracil (5-FU) plus folinic acid (FA) both have proven activity in the treatment of patients with advanced pancreatic cancer. The present study was initiated to investigate the efficacy of gemcitabine in combination with 5-FU-FA.
Introduction
Pancreatic cancer is the fifth leading cause of cancer death with age-adjusted yearly incidence rates of 5-10/ 100,000/year in the US and Europe [1] . Surgery provides the only chance of a cure. However, over 80% of patients with pancreatic cancer present with non-resectable, locally advanced or viscerally involved metastatic disease [2] . Less than 15% of newly diagnosed patients will survive one year and less than 5% will survive five years [3, 4] . The response rates achieved using conventional radiotherapy and chemotherapy strategies remain poor [5] [6] [7] [8] .
The most frequently used chemotherapy for pancreatic cancer has long been 5-fluorouracil (5-FU), with or without folinic acid (FA), but response rates have rarely exceeded 20% with no consistent effect on either diseaserelated symptoms or survival [9] [10] [11] [12] . The results obtained with 5-FU combination regimens have been no better than those obtained with 5-FU alone and are associated with much greater toxicity [13] [14] [15] [16] .
The novel nucleoside analogue gemcitabine (Gemzar®) has shown promising activity in the treatment of these patients [17] [18] [19] [20] [21] . In a phase II study of 44 patients with advanced pancreatic cancer, gemcitabine not only showed a relatively high one-year survival (23%), but also a positive effect on tumour-related symptoms [17] . In another phase II study in 63 patients with 5-FU refractory pancreas cancer, 17 patients (27%) achieved a clinical benefit response with a median duration of 14 weeks [19] , demonstrating a lack of cross-resistance between 5-FU and gemcitabine. In a randomised study, singleagent gemcitabine was shown to be superior to singleagent 5-FU in the treatment of patients with advanced pancreatic cancer [20] . Patients treated with gemcitabine had a significantly better clinical benefit response, derived from measurement of pain, functional impairment and weight loss, than those treated with 5-FU (23.8% vs. 4.8%) [20] . Disease stabilisation was seen in 39% and 19% of the gemcitabine-and 5-FU-treated patients, respectively. The mild toxicity profile of gemcitabine and lack of cross-resistance with 5-FU [19, 20] make it an obvious partner for combination therapy with 5-FU in the treatment of these patients. Moreover, there is reported synergy between gemcitabine and 5-FU in vitro [22] . The combination of gemcitabine in combination with 5-FU-FA was chosen with the hope that modulation of 5-FU by FA would translate into a higher cytostatic activity in the tumour cells than achieved by gemcitabine and 5-FU alone.
The aim of the present study was to follow on from our phase I study [23] , and investigate the efficacy and toxicity profile of the combination of weekly gemcitabine, 1000 mg/m 2 , delivered with FA, 200 mg/m 2 and 24-hour continuous infusion 5-FU (750 mg/m 2 ).
Patients and methods

Patient eligibility
Patients were eligible for entry into the study if they met the following /l and hemoglobin 3=80 g/I). Written informed consent had to be provided by all patients. Patients with endocrine tumors of the pancreas or lymphoma of the pancreas were excluded from this study. Central nervous system metastases and second primary malignancies were also criteria for exclusion, as were inadequate liver function, pregnancy, active infection or other serious concomitant disorder. This study received approval from the local ethical committee.
Treatment
Prior to study entry, all patients had a full blood count and prothrombin time measurements. Blood chemistries were measured and urine analysis performed. Prior to treatment, the disease state of each patient was assessed. Tumor measurement was carried out by computerised tomography (CT) or magnetic resonance imaging (MRI).
Gemcitabine (Gemzar®, Eli Lilly and Company, USA, 1000 mg/ m 2 ) was administered as a 30 minute infusion, followed by 200 mg/m 2 folinic acid (Rescuvolin®, Medac, Germany) administered over two hours on days 1, 8, 15, and 22 of a 42-day schedule. A portable batterydriven pump (Walkmed™ 300) was used to administer 5-FU (Medac, Germany) (750 mg/m 2 ) as a 24-hour continuous infusion on days 1, 8, 15, and 22 of a 42-day schedule. This deviation from the more usual 28-day schedule for gemcitabine was used in the phase I study to increase the level of exposure to the drug, and also to improve quality of life, by allowing the patients three weeks (days 23-42) without therapy on a treatment schedule administered with purely palliative intent. Treatment was maintained until disease progression. Patients who progressed and who had a KPS of 3=80, were offered further chemotherapy. Those that wished to, received paclitaxel (Taxol K , Bristol Myers Squibb) monotherapy until disease progression.
Patient assessment and response evaluation
Efficacy was assessed throughout the treatment by limited physical examination, weekly weight measurement and performance status evaluation. Patients who had received at least one dose each of gemcitabine, 5-FU and FA were considered evaluable for efficacy and safety. A full blood count was taken on each day of treatment and blood chemistries at the start of each cycle. Dose reductions of gemcitabine and 5-FU were calculated on the basis of World Health Organisation (WHO) haematological evaluations, together with a clinical assessment of non-haematological toxicity. In the case of WHO grade 2 platelet toxicity and grade 3 leucocyte toxicity, the doses of both gemcitabine and 5-FU were reduced by 25%. In the case of WHO grade 3 non-haematological toxicity (except nausea, emesis and alopecia) both drugs were reduced by 50%. Patients were discontinued from therapy when treatment was associated with unacceptable WHO grade 3 or 4 toxicity, or at patient or investigator request. CTor MRI was used to define responses according to WHO criteria, and measurements were performed every six to eight weeks after initial assessment. Karnofsky performance measurements, made at the onset of the study and prior to each drug treatment, were used as a measure of patient well being.
Endpoints and statistics
The primary endpoint of this study was time to progression (TTP). Toxicity, response-rate and overall survival were secondary endpoints. TTP and survival were analysed using Kaplan-Meier estimations as described previously [23] .
Data from the literature [20] , suggest a median TTP for gemcitabine monotherapy in pancreatic cancer patients of approximately three months. Based on our phase I experience we did not anticipate a significant increase in response rate, but wanted to test the hypothesis that using the present regimen 3= 75% of patients would be progression-free three months after the start of treatment. It was calculated that 38 evaluable patients would have to be recruited to yield an 90% power of detection with an a error of 0.05.
Results
Thirty-eight patients were enrolled into this multi-centre study (8 centres) in Germany. The baseline characteristics of all patients are summarised in Table 1 . All 38 patients had stage IV disease, with 31 of 38 having advanced metastatic disease. The median age was 60 years (range . No patient had received prior chemotherapy or radiotherapy. All 38 patients were evaluable for response-rate, toxicity and time to progressive disease.
The median number of treatment cycles administered per patient was 3 (range 1-12). The total number of cycles administered was 143. Eighty-eight percent (506 of 572) of drug administrations were made as planned. There were 26 dose reductions (4.5%) in 9 patients and 39 therapy pauses (6.8%) in 16 patients. In the case of the therapy pauses, only 15 in 6 out of 16 patients were due to toxicity (grade 3 hepatotoxicity in 2 patients, and combined haematological toxicities consistently approaching grade 3 thrombocytopenia and grade 4 leucopenia, in 4 patients). The majority of the therapy pauses (24 in 10 patients) were made as a result of patient demand (holiday prolongation) or were due to stent problems (3 patients) and port problems (2 patients). The overall incidence of grade 3 and 4 toxicities was low (Table 2) . No patient was withdrawn from treatment due to toxicity. a Twenty-seven patients with hepatic metastasis, one patient with neck and hepatic metastasis, two with pulmonary metastasis (bilateral), one patient with hepatic and pulmonary metastasis. 
Efficacy
There were no complete responses in this study. However, two patients achieved partial responses of eight and three and a half months duration both achieved after the second cycle of therapy. Thirty-four out of thirty-eight patients (89%) achieved stable disease (Table 3) and were treated with a median of 3 cycles (range 2-12) of therapy. There were two early deaths at two weeks and four weeks due to disease progression. The median time to progression was 7.1 (0.4-18.1+) months for all patients. Including the 2 early deaths, 8 of 38 patients (21%) had progressed within 3 months, 16 of 38 patients (42%) had progressed within 6 months and 27 of 38 (71%) had progressed within 9 months (Table 3 and Figure 1 ). Three patients had a progression-free interval of more than twelve months (12.25, 15.5+, 18.1+). Overall 12 of 38 patients (32%) survived longer than 12 months (Figure 2) . Eight stage IVb patients received second-line paclitaxel therapy. Four (50%) of these patients survived longer than twelve months. All but seven patients (79%) showed a sustained (>4 weeks) improvement in their KPS (data not shown). In six patients the KPS remained stable and in one patient it decreased from 70 to 60. The two patients who succumbed early in the study to progressive disease (at 2 and 4 weeks), both had a KPS of 60 at the start of the study.
Discussion
Gemcitabine has proven activity in the treatment of pancreatic cancer, in terms of clinical benefit, response rate and survival [17, 19, 20] , and is rapidly becoming the standard therapy for advanced pancreatic cancer world-wide. However, there is still room for improvement in the treatment strategies for this patient group for whom the clinical outcome remains extremely poor. Recent evidence however suggests that gemcitabine when used in combination with other agents active in the treatment of pancreatic cancer may have an even greater impact on response and survival in these patients.
In the present study, gemcitabine in combination with 5-FU-FA provided effective treatment, with low toxicity, which could be delivered on an outpatient basis to a group of patients with an extremely poor prognosis (31 of 38 with grade 4b disease). Because of the difficulty in radiologically determining complete and partial responses in these patients and because gemcitabine was known not to have a curative role in these patients, TTP was chosen as the most meaningful primary endpoint. However, two patients did achieve partial responses and 34 patients (89%) achieved stable disease with associated stabilisation of their metastatic disease. The median time to progression was 7.1 months compared with the 3.1 months observed for gemcitabine monotherapy [20] . Seventy-nine percent of patients in this study showed no evidence of disease progression at three months and ŝ eventy-nine percent of patients showed a stabalisation if not an improvement in their KPS. Furthermore, the toxicity profile in the present study was so mild that eight patients progressing on this regimen could receive second-line therapy with paclitaxel. The median overall survival was 9.3 months (range 0.5-26.5 months). Overall, 32% of patients, including four of those who received paclitaxel, were alive at one year compared with the 18% and 2% for gemcitabine monotherapy and 5-FU, respectively, reported in a randomised study [20] and the 17% reported for 5-FU-FA alone [11] .
These observations are consistent with and compare very favourably with reports from other studies of gemcitabine in combination with 5-FU with or without FA which have also yielded complete and partial responses, and high incidences of disease stabilisation. The median overall survivals for these studies were in the range 5.5-13 months [23, [25] [26] [27] [28] [29] [30] [31] [32] . Thus the combination of gemcitabine plus 5-FU plus or minus FA seems to be active in terms of disease stabilisation and survival in patients with advanced pancreatic cancer. However, the optimal infusion length for 5-FU regarding efficacy and side effects has yet to be defined.
Gemcitabine used in combination with cisplatin in the treatment of patients with advanced pancreatic cancer has shown evidence of increased efficacy compared to gemcitabine alone with response rates in the range of 11.5% to 36.4% [33] [34] [35] , but with an essentially equivalent clinical benefit response (CBR) in one study [35] and median survivals in the range 7.4-8.3 months [33, 34] and essentially equivalent to those reported for 5-FU-FA. In all these studies the patients required hydration and treatment was associated with significant haematological toxicity, nephrotoxicity and alopecia. Gemcitabine in combination with docetaxel (Taxotere) gave response rates of 7.4%-33% [36] [37] [38] , but again these were associated with significant haematological toxicity. The median survival was seven months in one study [36] . Gemcitabine in combination with epirubicin has yielded response rates in the range 19%-25% and CBR in 40%-45% of patients again associated with high haematological toxicity [39, 40] . Gemcitabine in combination with cisplatin, epirubicin and 5-FU has yielded even higher response rates, but with significant toxicity [41] .
In conclusion, the present combination regimen appears to offer an equivalent survival advantage to those cited above, but associated with less toxicity. Dose reductions and therapy pauses were extremely low in this study, with 88% of drug administrations being made as planned. There were no patient withdrawals due to toxicity. Although clinical benefit response as introduced by Burris [21] was not measured prospectively in these patients, the overall opinion of the investigators was that most patients experienced a clinical benefit. All patients using this combination and schedule could be treated on an outpatient basis. The levels of fatigue were low, and there was no indication that older patients (> 60 years) tolerated the therapy less well than the younger patients or that the efficacy was reduced in these patients (data not shown). Also, these encouraging results were obtained at a very low dose of 5-FU. It is already known that there are high levels of variation in interpatient plasma concentrations [42] and a strong correlation between 5-FU dose and response [43] . Individual 5-FU dose adjustments and pharmacokinetic monitoring have been shown in advanced colorectal cancer patients to increase response and survival, in the absence of high toxicity [43] . Thus, it could be envisaged that in the future, in selected pancreatic cancer patients where no adverse toxicity was observed, that the dose of 5-FU could be increased with the promise of enhanced activity.
In summary, gemcitabine in combination with 5-FU-FA using this schedule provides one of the most effective therapies currently available for patients with advanced disease and should be investigated with individual 5-FU dose adjustment and in randomised phase III studies versus gemcitabine monotherapy and other gemcitabine combinations.
